ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3043

IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis

Ali Ugur Unal1, Rabia Deniz2, Aysin Tulunay Virlan3, Filiz Ture Ozdemir3, Imren Aydin Tatli3, Gulsen Ozen1, Fatma Alibaz-Oner4, Gonca Mumcu5, Tulin Ergun6 and Haner Direskeneli1, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 5Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 6Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Behcet's syndrome, immunology, interleukins (IL) and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-17 (IL-17) has been associated with the pathogenesis of  various inflammatory diseases. The aim of our study was to investigate the expression of Th17-related immunity in two phenotypically different disorders: Behcet’s disease (BD) with innate responses and Takayasu’s arteritis (TAK) with adaptive immunity.

Methods: The study population consisted of  three groups: patients with BD (n=37, age: 39.2 ±10.1 years), patients with TAK (n=25, age: 50.9 ±15.5 years) and healthy controls (HC) (n=25, age 40.9± 6.9 years). Peripheral blood mononuclear cells (PBMC) from patients with BD, TAK and HC were cultured in Th17 inducing condition (IL-6, PHA, IL-1b and IL-23) for 6 days.  Cultured cells were then stained  with CD4, CD8, CD3, TCRgd, CD19 IFN-ɣ and IL-17 antibodies to determine the intracellular cytokine secretion by flow cytometry.

Results: In BD patients, IL-17 expression by CD4+ T cells was observed to be higher than both TAK patients and HC (8.9±10.6 vs 3.5±2.5 and 4.5±4.9, p=0.03 and p=0.02, respectively). IL-17 expression by gd+ (14.4±13.3 vs 6.3±4.4 and 6.1±4.1, p=0.001, p<0.001 respectively) and CD8+T cells (7.0±8.3 vs 3.6±3.8 and 2.3±2.1, p=0.007 and p<0.001, respectively) was also higher in BD compared to TAK and HC. No differences were observed between the groups in the IL-17 production by B cells. Under Th17 inducing conditions, production of IFN-ɣ by CD4+ T cells (4.8±5.2 vs 2.0±1.7 and 1.9±1.3, p<0.05) and CD8 +T cells (11.3±12.6 vs 4.3±4.4 and 4.0±3.6, p<0.05) were also higher in both BD and TAK patients compared to the HC. No differences were observed between the groups in IFN-ɣ production by B cells and gd+ T cells. IL-17 expression and IFN-ɣ production in patients with BD and TAK under immuno-suppressive (IS) treatments were not different compared to patients without IS and HC (Table 1).

Conclusion: Our preliminary results suggest that under Th17 stimulating conditions, T cells express higher IL-17 levels in BD. More prominent IL-17 and IFN-ɣ production by all lymphocyte subsets in BD might be associated with the increased innate responses and early tissue neutrophil infiltrations in BD, which is not observed in TAK.  

Table 1. IL-17 expression and IFN-ɣ production in HC  and BD and TAK patients with and without IS treatment

 

HC

IS BD

Non-IS BD

IS TA

Non-IS TA

CD4+ IFN+

1.9±1.3

2.6±0.7

3.9±4.3

2.2±1.9

1.6±1.2

CD4+ IL-17+

4.5±4.9

7.8±8.5

8.9±11.3

3.3±2.3

3.5±3.1

CD8+ IFN+

4.0±3.6

6.1±2.6

10.2±12.1

5.2±5.0

3.3±3.1

CD8+ IL-17+

2.3±2.1

8.4±5.3

7.1±9.4

4.0±4.5

3.2±2.4

Gd+ IFN+

5.3±4.7

10.0±5.4

10.7±12.8

4.5±4.6

6.3±6.3

Gd+ IL17+

6.1±4.1

13.3±9.9

15.4±14.0

6.9±4.9

5.2±3.7


Disclosure: A. U. Unal, None; R. Deniz, None; A. Tulunay Virlan, None; F. Ture Ozdemir, None; I. Aydin Tatli, None; G. Ozen, None; F. Alibaz-Oner, None; G. Mumcu, None; T. Ergun, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Unal AU, Deniz R, Tulunay Virlan A, Ture Ozdemir F, Aydin Tatli I, Ozen G, Alibaz-Oner F, Mumcu G, Ergun T, Direskeneli H. IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/il-17-expression-by-lymphocytes-is-higher-in-behcets-disease-compared-to-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-17-expression-by-lymphocytes-is-higher-in-behcets-disease-compared-to-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology